How expanded use of GLP-1s could affect long-term outlooks for Eli Lilly and Novo Nordisk

Just a few short years after coming to market, the latest GLP-1 drugs are showing versatility in battling diseases related to diabetes and obesity, lifting the fortunes and expectations for market leaders Novo Nordisk (NVO) and Eli Lilly (LLY).